Two new medications, called lecanemab and donanemab, have shown success in clinical trials in slowing down Alzheimer’s disease. These are known as disease-modifying treatments and have been licensed ...

If you already have a place in this event but would like to support Alzheimer’s Research UK, we’d love to have you on the team! There’s no minimum sponsorship target and we can provide help and ...

Welcome to the Thames Valley Network Centre. The Network Centre unites dementia researchers across the Universities of Oxford, Reading and Oxford Brookes. Here you can find out more about Network ...

All applications for funds are reviewed by the Organising Committee, with conflicts of interest appropriately managed. New opportunities for 2025 Pump Priming awards, Equipment and Travel Awards will ...

Vascular dementia is the second most common type of dementia. Most cases of vascular dementia are not caused by directly inherited faulty genes. Vascular dementia is caused by reduced blood flow to ...

If you already have a place in this event but would like to support Alzheimer’s Research UK, we’d love to have you on the team! There’s no minimum sponsorship target and we can provide help and ...

There are two main types of Alzheimer’s. Late onset Alzheimer’s starts after age 65, and young onset Alzheimer’s affects people before age 65. Different genes can be involved in the development of the ...

If you already have a place in this event but would like to support Alzheimer’s Research UK, we’d love to have you on the team! There’s no minimum sponsorship target and we can provide help and ...

Dementia with Lewy bodies is the third most common disease that causes dementia. Both risk genes and faulty genes can be involved in dementia with Lewy bodies. Dementia with Lewy bodies (DLB) is ...

You can navigate our research funding dashboard to find the answers to these and other questions. The dashboard provides information on all the research projects we have funded, and are funding right ...